Patients on one-fourth the dose tested in large clinical trials have 20 to 25 percent increase in survival Findings are opposite of what was expected Beta-blocker dosing likely needs to be ...

Please provide your email address to receive an email when new articles are posted on . New findings from the OBTAIN registry demonstrate similar survival outcomes after acute MI among patients ...

"We set out on a mission to show if you treat patients with the doses that were used in the clinical trials, they will do better," says Jeffrey Goldberger. "We expected to see patients treated with ...

CHICAGO –For nearly 40 years a class of drugs known as beta blockers have been proven to increase patients' survival prospects following a heart attack by decreasing the cardiac workload and oxygen ...

Please provide your email address to receive an email when new articles are posted on . Beta-blocker therapy did not improve survival beyond 1 year after an MI, although a dose-dependent effect was ...

If there is a benefit to continuing beta-blockers beyond 1 year after acute MI, it might come with a lower dose. And for patients with LV dysfunction after STEMI, mineralocorticoid receptor ...

In a surprising finding, heart attack patients treated with a substantially lower dosage of beta-blockers than used in earlier clinical trials showing their effectiveness survived at the same rate, or ...